Kristin M. Morder

Kristin M. Morder

Auto-generated profile, based on publicly available information

Kristin M. Morder

University of Pittsburgh, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in Cancer Discovery
Verified
Journal Article
Open access
KMKristin M. Morder
Kristin M. Morder
MNMadison Nguyen
Madison Nguyen
DWDrew N. Wilfahrt
Drew N. Wilfahrt
ZDZakaria Larbi Dahmani
Zakaria Larbi Dahmani
ABAnsen B.P. Burr
Ansen B.P. Burr
AOAbigail E. Overacre-Delgoffe
Abigail E. Overacre-Delgoffe
Gut microbiota composition is directly associated with response to immunotherapies in cancer. The impact of diet on the gut microbiota and downstream immune responses to cancer remains unclear. In this study, we show that consumption of a common nonnutritive sweetener, sucralose, modifies microbiome composition, restricts T-cell metabolism and function, and limits immunotherapy response in preclinical models of cancer and patients with advanced cancer treated with anti–PD-1–based immune checkpoint inhibitors. Sucralose consumption is associated with a reduction in microbiota-accessible arginine, and amino acid supplementation or fecal microbiome transfer from anti–PD-1 responder mice completely restores T-cell function and immunotherapy response. Overall, sucralose consumption destabilizes the gut microbiota, resulting in compromised T-cell function and ablated immune checkpoint inhibitor response in cancer. Significance: This study highlights an unappreciated role of sucralose in reducing immunotherapy efficacy in both mouse models and samples from patients with cancer through shifts in the microbiome and arginine degradation that lead to T-cell exhaustion. T-cell function and immunotherapy responses are restored through amino acid supplementation. See related commentary by Chandra et al., p. 2196

3 April 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RFRicardo Jose Ferrari
Ricardo Jose Ferrari
GCGuangzhi Cong
Guangzhi Cong
ACAnsuman Chattopadhyay
Ansuman Chattopadhyay
BXB. Xie
B. Xie
EAE. Assaf
E. Assaf
USUlka Sachdev
Ulka Sachdev

2 November 2023
Verified
Conference Paper
Open access
PDF file
KMKristin Morder
Kristin Morder
DWDrew Wilfahrt
Drew Wilfahrt
BXBingxian Xie
Bingxian Xie
DDDiwakar Davar
Diwakar Davar
HNHector Nieves-Rosado
Hector Nieves-Rosado
AOAbigail E Overacre-Delgoffe
Abigail E Overacre-Delgoffe
Background Immunotherapy has revolutionized patient treatment across cancer types; however, the majority of patients still do not respond, and the reasons for this are unclear. The gut microbiota has been linked to immunotherapy response in melanoma, but the contributing factors to a ‘pro’ or ‘anti’ tumor microbiome remain unknown. Dietary factors, most notably, fiber intake, have been shown to support anti-tumor immunity, while diets high in fat or sugars are associated with poor response. Interestingly, artificial sweeteners (sucralose, saccharin), previously considered to be inert, were recently shown to dysregulate the gut microbiome. Therefore, we hypothesized that microbiome shifts due to artificial sweetener consumption may limit anti-tumor immunity and immunotherapy response in cancer. Methods Using a mouse model of anti-PD1 responsive cancer (MC38), we sought to determine the impact of sucralose consumption on immunotherapy efficacy. We administered sucralose in the drinking water of mice during tumorigenesis and anti-PD1 treatment and assessed tumor burden, survival, and immune infiltration via spectral immunofluorescence. Lymphocytes were isolated from the tumor and surrounding tissues on day 15 for 5’ single cell RNAseq and flow cytometry to assess TCR clonality and T cell function. We assessed potential direct impacts of sucralose on T cells and tumor cells through in vitro cell killing and functional assays. In addition, we characterized shifts to the gut microbiome and metabolites through 16S rRNAseq and metabolomics from the stool during tumor progression and anti-PD1 treatment. Results Sucralose, but not sucrose, supplementation in the drinking water ablated response to anti-PD1 in the MC38 mouse model (40–60% CR in controls, 10–20% CR in sucralose). Interestingly, this phenotype could be recapitulated through select antibiotic treatment or fecal microbe transfer (FMT) from sucralose treated animals. Sucralose reduced T cell functionality [cytokine production, proliferation, and cell killing] and increased T cell exhaustion [inhibitory receptor expression, loss of mitochondria] within the tissue. Most notably, we have found that sucralose consumption correlates with lack of response to immunotherapy in melanoma patients treated with anti-PD1. Conclusions Here, we demonstrate for the first time that supplementation of artificial sweeteners leads to drastic shifts in the gut microbiome and a significant reduction in anti-PD1 response in both mouse and man. The gut microbiome is both necessary and sufficient for this loss of response, indicating that artificial sweeteners may represent a barrier to effective immunotherapy. Overall, these findings suggest that select dietary intervention or FMT may be required to boost response to current checkpoint inhibitors.

3 November 2025
Verified
Other
Open access
PDF file
KMKristin M. Morder
Kristin M. Morder
MNMadison Nguyen
Madison Nguyen
DWDrew N. Wilfahrt
Drew N. Wilfahrt
ZDZakaria Larbi Dahmani
Zakaria Larbi Dahmani
ABAnsen B.P. Burr
Ansen B.P. Burr
AOAbigail E. Overacre-Delgoffe
Abigail E. Overacre-Delgoffe
Appendix 3 shows the IRB approval for HCC 17 to 169.

3 November 2025
Verified
Other
Open access
PDF file
KMKristin M. Morder
Kristin M. Morder
MNMadison Nguyen
Madison Nguyen
DWDrew N. Wilfahrt
Drew N. Wilfahrt
ZDZakaria Larbi Dahmani
Zakaria Larbi Dahmani
ABAnsen B.P. Burr
Ansen B.P. Burr
AOAbigail E. Overacre-Delgoffe
Abigail E. Overacre-Delgoffe
Supplementary Fig S8 shows T cell proliferation, function, and metabolism following culture in sucralose.

3 November 2025
Verified
Other
Open access
PDF file
KMKristin M. Morder
Kristin M. Morder
MNMadison Nguyen
Madison Nguyen
DWDrew N. Wilfahrt
Drew N. Wilfahrt
ZDZakaria Larbi Dahmani
Zakaria Larbi Dahmani
ABAnsen B.P. Burr
Ansen B.P. Burr
AOAbigail E. Overacre-Delgoffe
Abigail E. Overacre-Delgoffe
Appendix 2 shows the full protocol for HCC 20-019.